Research Article
Prognostic Value of Circulating Tumour DNA in Asian Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Table 1
General characteristics of the study populations.
| | First author and publication year | Country | Ethnicity | No. of patients | TNM stage | Sample origin | Time of sample collected | Detection methods | Treatment | Marker | Endpoints | Survival data type | NOS score | | Survivorship curve | Univariate | Multivariate |
| | Hirai 2020 [30] | Japan | Asian | 130 | II–IV | Plasma | Posttreatment | ddPCR | Chemotherapy | TERT | OS | 2.34 (1.46–4.02) | 2.19 (1.36–3.61) | 1.94 (1.18–3.24) | 8 | | Wang 2020 [23] | China | Asian | 81 | I–IV | Plasma | Pretreatment | ddPCR | Surgery | ctDNA | OS | 6.82 (2.67–17.42) | 6.52 (2.52–16.87) | 4.20 (1.50–11.80) | 8 | | DFS | 5.46 (2.49–12.56) | NA | NA | | Ako 2020 [28] | Japan | Asian | 36 | I–III | Serum | Pretreatment | ddPCR | Surgery | TERT | DFS | NA | 3.28 (1.23–11.3) | 3.01 (1.11–10.5) | 7 | | Wei 2018 [25] | China | Asian | 119 | NA | Plasma | Pretreatment | MSP | Surgery | SOCS3 | OS | 1.12 (0.98–2.44) | NA | NA | 7 | | DFS | 2.64 (1.14–3.48) | NA | NA | | Huang 2011 [24] | China | Asian | 72 | I–IV | Plasma | Pretreatment | Real-time PCR | Surgery | ctDNA | OS | 1.34 (0.96–2.34) | NA | NA | 7 | | Rem 2006 [22] | China | Asian | 79 | I–IV | Plasma | Pretreatment | Ultraviolet transilluminator | Surgery | ctDNA | OS | 2.46 (1.26–4.56) | NA | NA | 7 | | | DFS | 1.96 (1.32–3.23) | NA | NA | | An 2019 [29] | China | Asian | 26 | I–IV | Plasma | Pretreatment | Qubit fluorometer | Surgery | ctDNA | DFS | 3.16 (1.46–6.42) | NA | NA | 7 | | Cai 2019 [21] | China | Asian | 34 | I–IV | Plasma | Pretreatment | Illumina sequencing | Surgery + other adjuvant therapies | ctDNA | OS | 11.86 (2.84–47.51) | 12.08 (2.92–46.25) | 10.69 (2.84–45.81) | 8 |
|
|
ddPCR, droplet digital PCR; DFS, disease-free survival; OS, overall survival; NA, data not applicable.
|
